Fox Chase Researchers Study Tumor Characteristics and Next-Generation Sequencing as Markers for Immunotherapy Response
PHILADELPHIA (August 28, 2020)—In a recently published study, researchers at Fox Chase Cancer Center and Temple University investigated whether the use of next-generation sequencing and primary tumor characteristics could help better predict the efficacy of immunotherapy.